Therapy Areas: Respiratory
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
7 March 2025 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) said on Friday that it has received approval from Health Canada for its ACARIZAX tablet to treat children aged five...
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
6 March 2025 - Clinical-stage pharmaceutical company Plus Therapeutics Inc (Nasdaq:PSTV) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
4 March 2025 - Chinese biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) announced on Monday that the first patient has been dosed in the global multicentre Phase I clinical trial of its no...
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment
3 March 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has received a positive recommendation from the European Medicines Agency'...
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
28 February 2025 - Swedish bioinformatics software provider Qlucore AB (Nasdaq First North Growth Market:QCORE) on Friday introduced the first CE-marked diagnostic test for paediatric leukaemia under ...
Novita Pharmaceuticals reveals additional results from Phase 2 trial in patients with advanced and metastatic solid tumours
26 February 2025 - Clinical-stage pharmaceutical company Novita Pharmaceuticals Inc on Tuesday reported additional results from its Phase 2 study assessing NP-G2-044 in combination with SOC anti-PD-1 ...